FDA warns about rare but severe lung inflammation with palbociclib, ribociclib, and abemaciclib for breast cancer -

FDA warns about rare but severe lung inflammation with palbociclib, ribociclib, and abemaciclib for breast cancer
Information type: Safety alerts
Source: US Food and Drug Administration
Specialities: Cancers | Respiratory disorders
Summary
A review has identified reports of serious cases of interstitial lung disease (ILD) and pneumonitis, including fatalities with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor medicines. However, the overall benefit of CDK 4/6 inhibitors is still greater than the risks when used a
UKMi comment
Healthcare professionals are advised to monitor patients, to interrupt treatment in patients with new or worsening respiratory symptoms, and discontinue treatment in patients with severe ILD and/or pneumonitis.
Related links: